Cutera, Inc.

DB:TJ9 Stock Report

Market Cap: €6.1m

Cutera Valuation

Is TJ9 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of TJ9 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate TJ9's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate TJ9's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for TJ9?

Key metric: As TJ9 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for TJ9. This is calculated by dividing TJ9's market cap by their current revenue.
What is TJ9's PS Ratio?
PS Ratio0.04x
SalesUS$155.21m
Market CapUS$6.39m

Price to Sales Ratio vs Peers

How does TJ9's PS Ratio compare to its peers?

The above table shows the PS ratio for TJ9 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average5.2x
AUG Audientes
12.6xn/a€6.9m
GME Geratherm Medical
0.9x1.9%€16.5m
AAQ1 aap Implantate
1.9xn/a€22.4m
NN6 NanoRepro
5.3xn/a€18.9m
TJ9 Cutera
0.04x2.4%€6.4m

Price-To-Sales vs Peers: TJ9 is good value based on its Price-To-Sales Ratio (0x) compared to the peer average (2.7x).

Price to Sales Ratio vs Industry

How does TJ9's PS Ratio compare vs other companies in the DE Medical Equipment Industry?

5 CompaniesPrice / SalesEstimated GrowthMarket Cap
Industry Avg.3.4x6.0%
TJ9 Cutera
 0.04x2.4%US$6.39m
DRW3 Drägerwerk KGaA
0.2x4.2%US$836.09m
PHH2 Paul Hartmann
0.3xn/aUS$779.09m
TJ9 0.0xIndustry Avg. 3.4xNo. of Companies4PS01.63.24.86.48+
5 CompaniesEstimated GrowthMarket Cap
Industry Avg.3.4x14.2%
TJ9 Cutera
 0.04x26.5%US$6.39m
No more companies

Price-To-Sales vs Industry: TJ9 is good value based on its Price-To-Sales Ratio (0x) compared to the European Medical Equipment industry average (3.4x).

Price to Sales Ratio vs Fair Ratio

What is TJ9's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

TJ9 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio0.04x
Fair PS Ratio0.09x

Price-To-Sales vs Fair Ratio: TJ9 is good value based on its Price-To-Sales Ratio (0x) compared to the estimated Fair Price-To-Sales Ratio (0.1x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst TJ9 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€0.30
€1.40
+372.3%
33.3%€1.87€0.93n/a2
Nov ’25€0.53
€1.35
+157.5%
33.3%€1.81€0.90n/a2
Oct ’25€0.69
€1.35
+96.1%
33.3%€1.81€0.90n/a2
Sep ’25€0.70
€2.44
+250.6%
63.7%€4.58€0.92n/a3
Aug ’25€1.26
€5.88
+365.3%
45.3%€9.28€2.78n/a3
Jul ’25€1.37
€5.88
+328.8%
45.3%€9.28€2.78n/a3
Jun ’25€1.88
€5.88
+212.6%
45.3%€9.28€2.78n/a3
May ’25€2.15
€5.86
+172.6%
45.3%€9.25€2.78n/a3
Apr ’25€1.29
€5.86
+354.3%
45.3%€9.25€2.78n/a3
Mar ’25€2.04
€7.06
+246.2%
43.0%€9.21€2.76n/a3
Feb ’25€2.42
€7.06
+191.8%
43.0%€9.21€2.76n/a3
Jan ’25€3.30
€7.19
+117.9%
43.0%€9.38€2.81n/a3
Dec ’24€1.68
€7.19
+328.0%
43.0%€9.38€2.81n/a3
Nov ’24€2.94
€17.50
+495.4%
12.4%€19.87€14.19€0.534
Oct ’24€5.80
€20.96
+261.3%
25.5%€30.07€16.40€0.694
Sep ’24€10.50
€20.96
+99.6%
25.5%€30.07€16.40€0.704
Aug ’24€18.10
€23.93
+32.2%
35.6%€38.30€16.41€1.264
Jul ’24€13.90
€25.50
+83.5%
39.5%€38.25€12.75€1.374
Jun ’24€15.70
€25.50
+62.4%
39.5%€38.25€12.75€1.884
May ’24€19.80
€34.39
+73.7%
15.0%€41.63€29.87€2.153
Apr ’24€21.60
€44.47
+105.9%
27.7%€64.18€30.26€1.294
Mar ’24€27.00
€45.77
+69.5%
24.6%€65.65€30.95€2.045
Feb ’24€32.00
€51.80
+61.9%
23.5%€64.52€30.42€2.425
Jan ’24€40.60
€67.49
+66.2%
14.5%€80.12€51.84€3.305
Dec ’23€45.40
€73.87
+62.7%
14.2%€85.31€55.20€1.685
Nov ’23€46.60
€75.27
+61.5%
14.2%€86.93€56.25€2.945

Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.

Discover undervalued companies

LNA Santé

€244.9m

Engages in the management and operation of health establishments.

2N3

€23.30

7D

-5.3%

1Y

19.1%

Shandong Weigao Group Medical Polymer

HK$19.8b

Engages in the research and development, production, wholesale, and sale of medical devices in the People’s Republic of China.

UK2

HK$0.51

7D

-10.5%

1Y

-38.6%

Top Glove Corporation Bhd

RM 7.8b

An investment holding company, manufactures, trades in, and sells gloves in Malaysia, Thailand, the People’s Republic of China, and internationally.

5OU

RM 0.98

7D

0.5%

1Y

-82.5%